

INVENTORS

Bert O'Malley MD, David
Michael Lonard PhD, Jin Wang
PhD, Jianming Xu PhD,
Jianwei Chen PhD

Molecular and
Cellular Biology

Publications
[Link to PubMed](#)

In-vivo experiments for
pancreatic, lung, brain,
and melanoma

Seeking commercial
partner through product
development and to
clinic

1 issued US patent and
several filings in
progress



SCAN ME

Novel small molecule inhibitors for use in multiple cancers


Potent, selective, small molecule inhibitors of steroid receptor co-activators (SRC) as potential therapeutics for different types of cancers

INDICATIONS: Breast and pancreatic

COMPETITIVE ADVANTAGES

Our **proprietary SI-12** compound is **simpler** and **less costly** to manufacture, distribute, store, and administer to patients

- **Selectively toxic** to cancer cells
- **Targeted approach** of inhibiting SRC than chemotherapy or radiation therapy
- **Efficacy** in multiple *in vivo* cancer models




On average, SI-12 treated mice saw tumor growth reduced by 70% compared to control

VALUE PROPOSITIONS

Slows tumor progression by inhibiting cell growth and proliferation

- SI-12 was **well tolerated** with mice maintaining **stable body weight**
- **Best in class** inhibitor
- Tumor weight was **significantly less** with treatments versus control mice
- SI-12 has **anti-proliferative** activity in various cancers types
- Less destructive, more targeted, and **tolerable alternative** to traditional cancer treatments such as chemotherapy and radiation



INDUSTRY APPETITE

Majority of large pharma companies have products or pipeline therapies in the oncology small molecule space and are teaming with **Universities for development**

- SRC offers novel **pathway for inhibitors** like SI-12
- Oncology small molecule drugs are forecasted to **exceed \$82 billion**
- **Partner opportunity** with Loxo Oncology to bring this inhibitor technology to development
- Players in the space Eli Lilly, Pfizer, AMGEN, Merck, Johnson & Johnson
- February 2021: Jubilant Biosys and **Yale University** small molecule collab
- March 2021: **MD Anderson** and Orionis Bioscience repurpose small molecule

MARKET ANALYSIS

Current treatment options for pancreatic and breast cancer are surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.

\$125 Billion

Market estimates for **oncology small molecule drugs** by 2026 with US owning 50% market

57,600

People will be diagnosed with **pancreatic cancer** in US per year

7%

Pancreatic cancer accounts for 7% of all **cancer deaths** with 5-year survival rate after diagnosis